Abstracts

777 – The Impact of HIV Infection on All-Cause Mortality Among Individuals Treated for HBV in Rwanda

Background Chronic hepatitis B virus (HBV) infection increases the risk of severe liver diseases such as cirrhosis, hepatocellular carcinoma, non-liver complications, and mortality. HIV co-infection contributes to the acceleration of liver disease progression, leading to greater mortality risk compared to HBV mono-infection. We evaluated the crude all-cause mortality rates among people with chronic HBV on…

762 – Determinants of Steatotic Liver Disease Among People With HIV in Europe and Australia

Background Given the increased prevalence of steatotic liver disease (SLD) in people with HIV, understanding its natural course and progression to liver fibrosis is crucial for guiding clinical management.  Methods We assessed SLD and liver fibrosis in RESPOND participants from January 2012 to December 2022 using serological scores validated for people with HIV, excluding those with…

753 – Impact of HIV Infection on the Dynamics of Liver Stiffness After HCV Cure

Background During HCV active chronic infection, HIV co-infection promotes liver fibrogenesis and accelerates the progression towards cirrhosis. After sustained virological response (SVR), liver stiffness (LS) usually decreases, regardless of HIV co-infection. However, information related to the impact of HIV co-infection on LS dynamics in this subset is scarce. Methods Multicenter prospective study conducted in the…

763 – Diabetes Mellitus and Liver Disease Progression in PWH With Metabolic Dysfunction-Associated SLD

Background We investigated the risk of liver stiffness progression and advanced liver fibrosis (LF) by diabetes mellitus (DM) status among people with HIV (PWH) and metabolic-dysfunction associated stetotic liver disease (MASLD). Methods PWH who had MASLD at their first vibration-controlled transient elastography or VCTE with both liver stiffness measurement (LSM) and controlled attenuation parameter (CAP)…

774 – Increased Detection of HBV DNA and Mutational Analysis in HBsAg-Negative Specimens at NHLS/DGM

Background The disease burden associated with Hepatitis B (HBV) necessitates accurate diagnosis and it is important for effective disease management and prevention. The standard approach to HBV diagnosis is hepatitis B surface antigen (HBsAg) screening. However, the rising detection of HBV DNA in HBsAg negative specimens indicates a challenge. The underdiagnosis of HBV due to…

766 – Lipidomics of Metabolic Dysfunction-Associated Steatotic Liver Disease Post-HCV Eradication in PWH

Background Although sustained virologic response (SVR) following direct-acting antiviral (DAA) therapy is a key goal in treating hepatitis C, some patients continue to experience liver disease progression despite HCV clearance. Metabolic dysfunction-associated steatotic liver disease (MASLD) may contribute to this progression. This study aims to characterize the lipidomic profiles linked to MASLD in HIV/HCV-coinfected patients…

754 – Comorbidities Among Medicaid Enrollees With Chronic Hepatitis C, 2016-2020

Background To achieve hepatitis C elimination in the United States (US), understanding comorbidities among people living with chronic hepatitis C is crucial to inform prevention and treatment approaches. We aimed to quantify and characterize the prevalence of HIV, sexually transmitted infections (STIs), mental health disorders, substance use disorders, and drug overdose among Medicaid enrollees diagnosed…

710 – Preclinical Evaluation of an Ultra-Long-Acting Tenofovir Prodrug Nanosuspension

Background Effective treatment of hepatitis B (CHBV) infection requires adherence to long-term daily antiviral therapies. These include oral tenofovir (TFV) prodrugs [TFV disoproxil-/TFV alafenamide-fumarate – TDF/TAF] or entecavir. Treatment cessation leads to HBV reactivation and disease progression. This underscores the need for long-acting formulations to improve treatment outcomes. Considering these needs, we developed a scalable amino…